URGN Q3 2024 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$927M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$25M+20.9% YoY

Gross Profit

$23M90.3% margin

Operating Income

-$18M-69.6% margin

Net Income

-$24M-93.9% margin

EPS (Diluted)

$-0.55

QoQ Revenue Growth

+15.4%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$28M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$302M

Total Liabilities

$276M

Stockholders' Equity

$26M

Cash & Equivalents

$125M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$25M	$21M	+20.9%
Gross Profit	$23M	$18M	+23.1%
Operating Income	-$18M	-$14M	-30.0%
Net Income	-$24M	-$22M	-8.2%

Revenue Segments

Jelmyto

$25M100%